Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Prostate Cancer Therapeutics Market to Reach a Value of US$ 19.6 Bn by 2027: Says TMR

Transparency Market Research (TMR) has published a new report on the Prostate Cancer Therapeutics Market for the forecast period of 2019–2027. According to the report, the global prostate cancer therapeutics market was valued at ~US$ 9.6 Bn in 2018, and is projected to expand at a CAGR of ~8% from 2019 to 2027.


prostate cancer therapeutics market infographic

Download a PDF Sample of Report – 

Prostate Cancer Therapeutics Market: Overview

Prostate cancer is the most common non-cutaneous cancer occurring worldwide. New cases of prostate cancer account for one-third of all male cancer diagnoses and 10% of all deaths, globally.

Increase in cancer screening with prostate-specific antigen (PSA) is in part responsible for high localized staging of the disease at the time of diagnosis.

A majority of patients eventually become hormone refractory; however, the time in which androgen-insensitive clones emerge could range from months to years from the initiation of androgen-depravation therapy-ADT.

A number of different treatment modalities have been examined for prostate cancer. Each treatment has potential advantages as well as therapeutic limitations.

Rise in Prevalence of Prostate Cancer and Launch of Promising Emerging Therapies to Drive Market

Increase in life expectancy in developed countries has increased the geriatric population, which, in turn, has led to the high incidence of prostate cancer. According to the Prostate Cancer Foundation, a majority of prostate cancer cases are diagnosed in men over 65. Hence, consistent rise in the geriatric population and sedentary lifestyles of people in developed countries augment the prevalence of prostate cancer across the globe.

This increases the need and demand for prostate cancer therapeutics. According to the Urology Care Foundation, around 1 in 7 men is diagnosed with prostate cancer, and approximately one in 35 men succumb to the disease.

Inquire for a PDF Brochure of Report – 

Prominent players in the prostate cancer treatment market are emphasizing on R&D and the manufacture of therapeutics for the long-term survival of patients. Castration-resistant prostate cancer (CRPC) has driven the approvals of effective & potent systemic agents as first- and second-line treatments. Currently, numerous molecular agents are in the early phase of clinical trials for the treatment of prostate cancer. As of May 2016, the FDA had approved 13 new indications and four novel drugs in oncology, some of which are considered as first-in-class therapies.

Hormone Therapy to Dominate Market

In terms of therapy, the global prostate cancer therapeutics market has been classified into hormone therapy (luteinizing hormone-releasing hormone analogs, luteinizing hormone-releasing hormone antagonists, and antiandrogens), chemotherapy (systemic chemotherapy, regional chemotherapy), biologic therapy, and targeted therapy.

The hormone therapy segment dominated the market in 2018, and the trend is likely to continue during the forecast period.

Launch of new products in antiandrogens and luteinizing hormone-releasing hormone antagonists are projected to boost the growth of the hormone therapy segment.

Get Discount on Report – 

Hospital Pharmacies to be Promising Distribution Channels

In terms of distribution channel, the global prostate cancer therapeutics market has been divided into hospital pharmacies, retail pharmacies, online sales, and others. The hospital pharmacies segment is projected to be a highly lucrative segment of the global prostate cancer therapeutics market during the forecast period.

The hospital pharmacies segment is anticipated to grow at a rapid pace, as a majority of prostate cancer treatments are performed in hospitals, and these settings offer easy reimbursement procedures.

Growth Strategies of Key Players in Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is fragmented in terms of number of players. Key players operating in the global market are Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), Pfizer, Inc., AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., and Sanpower Group (Dendreon Corporation).

Pfizer, Inc. was the second-largest shareholder of the global prostate cancer therapeutics market in 2018. It is expected to dominate the global market in terms of supply of prostate cancer therapeutic products.

Oder Now, Prostate Cancer Therapeutics Market Report –

Janssen Biotech (Johnson & Johnson) accounted for the third-largest share of the global prostate cancer therapeutics market in 2018. Zytiga was the major brand sold for the treatment of prostate cancer.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Browse our Blogs for More Research Insights:

Tags: Global Prostate Cancer Therapeutics Market, Prostate Cancer Therapeutics Market, Prostate Cancer Therapeutics Market Share, Prostate Cancer Therapeutics Market Trends

See Campaign:
Contact Information:
Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website:

, Research Newswire, English


This post first appeared on ICrowdNewswire -, please read the originial post: here

Share the post

Prostate Cancer Therapeutics Market to Reach a Value of US$ 19.6 Bn by 2027: Says TMR


Subscribe to Icrowdnewswire -

Get updates delivered right to your inbox!

Thank you for your subscription